Preclinical and clinical properties of trimegestone: A potent and selective progestin

Gynecological Endocrinology

Volumn 23, Issue 6, 2007, Pages 310-319

  Sitruk Ware, Regine ^a   Bossemeyer, Ronald ^b   Bouchard, Phillipe ^c  

^a ROCKEFELLER UNIVERSITY   (United States)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Endometrial safety; Hormone therapy; Progestin; Trimegestone

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID; DROSPIRENONE; DYDROGESTERONE PLUS ESTRADIOL; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS NORETHISTERONE; ESTRADIOL VALERATE PLUS NORGESTREL; ESTROGEN; GESTAGEN; GESTODENE; LEVONORGESTREL; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MINERALOCORTICOID; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTREL; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR; STEROID HORMONE; STEROID RECEPTOR; TRIMEGESTONE; TRISEQUENS;

ABDOMINAL PAIN; BINDING AFFINITY; BLEEDING; BODY WEIGHT; BONE DENSITY; BREAST CANCER; CLINICAL STUDY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG WITHDRAWAL; GABAERGIC SYSTEM; HORMONAL THERAPY; HOT FLUSH; HUMAN; LOW DRUG DOSE; MASTALGIA; MENOPAUSAL SYNDROME; METRORRHAGIA; MOOD; MOOD CHANGE; NONHUMAN; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SLEEP; SOMNOLENCE; UTERUS BLEEDING; VASOMOTOR DISORDER;

AFFECT; ANIMALS; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; CHEMISTRY; DEPRESSION; DRUG THERAPY, COMBINATION; ENDOMETRIUM; ESTRADIOL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HOT FLASHES; HUMANS; PROGESTINS; PROMEGESTONE; RECEPTORS, PROGESTERONE; SLEEP; UTERINE HEMORRHAGE;

EID: 34447130134     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701267727     Document Type: Review

References (32)

1. Writing Group for the Women's Health Initiative Randomized Control Trial. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-333.
2. American College of Obstetricians and Gynecologists. Executive summary. Obstet Gynecol 2004;104:1S-131S.
3. International Menopause Society. Guidelines for the hormone treatment of women in the menopausal transition and beyond: position statement by the Executive Committee of the International Menopause Society. Maturitas 2004;48:27-31.
4. Gambacciani M, Spielmann D, Genazzani AR. Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17β-estradiol and trimegestone versus two regimens containing 1 or 2 mg 17β-estradiol and norethisterone acetate. Gynecol Endocrinol 2005;21:65-73.
5. Bouchard P, De Cicco-Nardone F, Spielmann D, Garcea N. Bleeding profile and endometrial safety of continuous combined regimens of 1 mg 17β-estradiol/trimegestone versus 1 or 2mg 17β-estradiol/ norethisterone in postmenopausal women. Gynecol Endocrinol 2005;21:142-148.
6. Koninckx PR, Spielmann D. A comparative 2-year study of the effects of sequential regimens of 1 mg 17β-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women. Gynecol Endocrinol 2005;21:82-89.
7. Pornel B, Spielmann D. A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17β-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a 2-year period. Gynecol Endocrinol 2005;21:74-81.
8. Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999;13:316-326.
9. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002;9:6-15.
10. Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 2003;68:915-920.
11. Zhang Z, Lundeen SG, Zhu Y, Carver JM, Winneker RC. In vitro characterization of trimegestone: a new potent and selective progestin. Steroids 2000;65:637-643.
12. Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 1995;51:99-110.
13. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 2003;68:891-905.
14. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004;47:277-283.
15. Lundeen SG, Zhang Z, Zhu Y, Carver JM, Winneker RC. Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone. J Steroid Biochem Mol Biol 2001;78:137-143.
16. McPhail MK. The assay of progestin. J Physiol 1934;83:145-156.
17. Zarrow MX, Yochim JM. The progestogens. In: Zarrow MX, Yochim JM, McCarthy JL, Sanborn RC, editors. Experimental endocrinology. New York: Academic Press; 1964. pp 65-108.
18. Lepescheux L, Secchi J, Gaillard-Kelly M, Miller P. Effects of 17β-estradiol and trimegestone alone, and in combination, on the bone and uterus of ovariectomized rats. Gynecol Endocrinol 2001;15:312-320.
19. Bouali Y, Gaillard-Kelly M, Marie PJ. Effect of trimegestone alone or in combination with estradiol on bone mass and bone turnover in an adult rat model of osteopenia. Gynecol Endocrinol 2001;15:48-55.
20. Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol 1995;7:171-177.
21. Bitran D, Shiekh M, Dowd JA, Dugan MM, Renda P. Corticosterone is permissive to the anxiolytic effect that results from the blockade of hippocampal mineralocorticoid receptors. Pharmacol Biochem Behav 1998;60:879-887.
22. Root E, Maul J, Fitzgerald S, et al. Psychotropic effects of pregnane steroids in animal models of anxiety. Soc Neurosci 2000;26:2038.
23. Sultan E, Perret C, Verdier P, Bonnat C, Pretorius S, Scholtz H, Mogilnicka E, Lenfant B. Pharmacokinetics of estradiol and trimegestone in postmenopausal women after multiple administration of 2 mg estradiol once a day for 14 days followed by 2 mg estradiol/0.5 mg trimegestone once a day for 14 days. Climacteric 1999;2(Suppl. 2):221.
24. Al-Azzawi F, Wahab M, Thompson J, Pornel B, Hirvonen E, Ylikorkala O, van der Mooren MJ, Dillon J, Magaril C. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric 2001;4:343-354.
25. Meuwissen JH, Beijers-De Bie L, Vihtamaki T, Tuimala R, Siseles N, Magaril C, The HS, Houben PW, Murga M, Spielmann D, et al. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone. Gynecol Endocrinol 2001;15:349-358.
26. Koninckx P, Spielmann D, Trimegestone 302 Study Group. A comparative 2-year study of the effects of sequential regimens of 1 mg 17β-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone upon the bleeding profile and endometrial safety in postmenopausal women. Gynecol Endocrinol 2005;21:82-89.
27. Hunter M. The women's health questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health 1992;7:45-54.
28. Warming L, Ravn P, Spielmann D, Delmas P, Christiansen C. Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause 2004;11:337-342.
29. Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol 2002;3:303-311.
30. Bush TL, Whiteman M, Flaws J. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001;98:498-508.
31. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
32. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44.